Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used throughout the course of disease progression. Zytiga [Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone] and Xtandi [Pfizer/Astellas’s enzalutamide]) are cornerstone treatments for mCRPC, and several clinical trials are evaluating their role in earlier stages of the disease. Several therapies are also being positioned for the untapped and potentially lucrative nonmetastatic CRPC setting. The late-phase pipeline for mCRPC has also become more dynamic with three PARP inhibitors (AstraZeneca’s Lynparza [olaparib], Clovis Oncology’s Rubraca [rucaparib] and Pfizer’s talazoparib) and one immune checkpoint inhibitor (Roche/Genentech/Chugai’s Tecentriq [atezolizumab]) entering Phase III development.
- What factors are driving and constraining market growth? Which new classes of agents will emerge over the forecast period, and what impact will they have on the overall market?
- How is prostate cancer currently managed, and how will treatment practices change in the future?
- What is the clinical and commercial potential of late-phase pipeline products and what will be their likely positioning in the market? How will new market entrants fare through 2026?
- What are the actionable remaining unmet needs affecting the management of prostate cancer? What are the key drug development and therapeutic opportunities?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.